Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
11 mars 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
30 juil. 2020 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, July 30, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...